Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 607-622

  Cárdenas, Andrés ^a,b   Arroyo, Vicente ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Arginine vasopressin; Ascites; Cirrhosis; Dilutional hyponatraemia; Nitric oxide; Noradrenalin; Norepinephrine; Renin angiotensin; Sodium retention

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN ANTAGONIST; ARGIPRESSIN; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; LOSARTAN; NATRIURETIC FACTOR; NITRIC OXIDE; SODIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST; WATER;

ARTERY BLOOD FLOW; ASCITES; DIET THERAPY; DISEASE SEVERITY; EDEMA; ELECTROLYTE DISTURBANCE; EXTRACELLULAR SPACE; GYNECOMASTIA; HEART OUTPUT; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; ISCHEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY VASCULAR RESISTANCE; LIVER CIRRHOSIS; LYMPH; MUSCLE CRAMP; NEUROENDOCRINE SYSTEM; PATHOGENESIS; PLEURA DISEASE; PLEURA EFFUSION; PORTAL HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SODIUM RESTRICTION; SODIUM RETENTION; SODIUM URINE LEVEL; SPLANCHNIC BLOOD FLOW; VASOCONSTRICTION; VASODILATATION; WATER DEPRIVATION; WATER RETENTION; ARTERY DILATATION; VASCULAR RESISTANCE;

EID: 0344308514     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00052-6     Document Type: Article

References (83)

1. Arroyo V, Ginès P, Planas R & Rodés J. Pathogenesis, diagnosis and treatment of ascites in cirrhosis. In Bircher J, Benhamou JP, McIntyre, N, Rizzetto M & Rodés, M (eds) Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford: Oxford University Press, 1999, pp 697.
2. Jiménez W, Clària J & Arroyo V. Experimental cirrhosis and pathogenesis of ascites formation in chronic liver disease. In Holstege A, Hahn EG & Scholmerich J (eds) Portal Hypertension. Dordrecht: Kluwer Academic, 1995, pp 15-25.
3. Claria J & Jimenez W. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In Arroyo V, Ginès P, Schrier RW & Rodés J (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 378-396.
4. Jiménez W, Martínez-Pardo A, Arroyo V et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 1985; 5: 245-250.
5. Gines P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. New England Journal of Medicine 1991; 325: 829-835.
6. Arroyo V & Cárdenas A. TIPS in the treatment of refractory ascites. In Arroyo, V, Bosch J, Brugera M, Rodés J & Sánchez-Tapias JM (eds) Treatment of Liver Disease. Barcelona: Masson, 1999, pp 43-51.
7. Cárdenas A, Bataller R & Arroyo V. Mechanisms of ascites formation. Clinical Liver Disease 2000; 4: 447-465.
8. Laine GA, Hall JT, Laine SH et al. Transinusoidal fluid dynamics in canine liver during venous hypertension. Circulation Research 1979; 45: 317-323.
9. Witte GA, Witte MH, Dumont AE et al. Lymph protein and experimental hepatic and portal venous hypertension. Annals of Surgery 1968; 168: 567-577.
10. Witte CL, Witte MH & Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 1980; 78: 1059-1068.
11. Harris NR & Granger DN. Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: Local factors in the formation of ascites. In Arroyo V, Ginès P, Rodés J & Schrier RW (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 351-362.
12. Varin F & Huet PM. Hepatic microcirculation in the perfused cirrhotic rat liver. Journal of Clinical Investigation 1985; 76: 1904-1912.
13. Huet PM, Goresky CA, Villenueve JP et al. Assessment of liver microcirculation in human cirrhosis. Journal of Clinical Investigation 1982; 70: 1234-1244.
14. Witte CL, Witte MH & Dumont AE. Estimated net transcapillary water and protein flux in the liver and intestine of patients with portal hypertension from hepatic cirrhosis. Gastroenterology 1981; 80: 265-272.
15. Korthuis RJ, Kinden DA, Brimer GE et al. Intestinal capillary filtration in acute and chronic portal hypertension. American Journal of Physiology 1988; 254: G339-G345.
16. Levy M & Allotey JB. Temporal relationships between urinary salt retention and altered systemic haemodynamics in dogs with experimental cirrhosis. Journal of Laboratory and Clinical Medicine 1978; 92: 560-569.
17. Pecikyan R, Kanzaki G & Berger EY. Electrolyte excretion during the spontaneous recovery from the ascitic phase of cirrhosis of the liver. American Journal of Medicine 1967; 42: 359-367.
18. Papper S. Hepatorenal syndrome. In Epstein M (ed.) The Kidney in Liver Disease, 2nd edn. New York: Elsevier Biomedical, 1983, pp 87-106.
19. Arroyo V & Rodés J. A rational approach to the treatment of ascites. Postgraduate Medical Journal 1975; 51: 558-562.
20. Ginès P, Fernández-Esparrach G, Arroyo V et al. Pathogenesis of ascites in cirrhosis. Seminars in Liver Disease 1997; 17: 175-189.
21. Bernardi M, Laffi G, Salvagnini M et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: A randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156-162.
22. Bernardi M, Trevisani F, Santini C et al. Aldosterone related blood volume expansion in cirrhosis before and after the early phase of ascites formation. Gut 1983; 24: 761-766.
23. Reynolds TB, Lieberman FL & Redeker AG. Functional renal failure with cirrhosis. The effect of plasma expansion therapy. Medicine (Baltimore) 1967; 46: 191-196.
24. Angeli P, Gatta A, Caregaro L et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. European Journal of Clinical Investigation 1990; 20: 111-117.
25. Dudley JF & Esler MD. The sympathetic nervous system in cirrhosis. In Arroyo V, Ginès P, Rodés J & Schrier RW (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 198-219.
26. Bernardi M, Trevisani F & Caraceni P. The renin-angiotensin-aldosterone system in cirrhosis. In Arroyo V, Ginès P, Rodés J & Schrier RW (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 175-197.
27. Girgrah N, Liu P, Collier J et al. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000; 46: 114-120.
28. Helmy A, Jalan R, Newby DE et al. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118: 565-572.
29. Bernardi M. Renal sodium retention in preascitic cirrhosis: Expanding knowledge, enduring uncertainties. Hepatology 2002; 35: 1544-1547.
30. Trevisani F, Bernardi M, DePalma R et al. Circadian variation in renal sodium and potasium handling in cirrhosis. The role of aldosterone, cortisol, sympathoadrenergic tone, and intratubular factors. Gastroenterology 1989; 96: 1187-1198.
31. Perez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of furosemide versus spironolactone in patients with liver cirrhosis and ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84: 961-968.
32. Wong F, Liu P & Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002; 35: 1449-1458.
33. Yang YY, Lin HC, Lee WC et al. One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. Journal of Gastroenterology 2002; 37: 194-199.
34. Henriksen JH, Moller S, Ring Larsen H et al. The sympathetic nervous system in liver disease. Journal of Hepatology 1998; 29: 328-341.
35. Esler M & Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Journal of the Autonomic Nervous System 1998; 72: 210-219.
36. Salò J, Ginès A, Anibarro L et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone and norepinephrine levels. Hepatology 1995; 22: 497-487.
37. Ginès P & Rodés J. Clinical disorders of renal function in cirrhosis with ascites. In Arroyo V, Ginès P, Rodés J & Schrier RW (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 36-62.
38. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264-272.
39. Arroyo V, Clària J, Saló J & Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Seminars in Liver Disease 1994; 14: 44-58.
40. Arroyo V, Rodés J, Gutiérrez-Lizarraga MA & Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. American Journal of Digestive Diseases 1976; 21: 249-256.
41. Cárdenas A & Ginès P. Treatment of water retention and dilutional hyponatraemia in cirrhosis. In Arroyo V, Bosch J, Brugera M, Rodés J & Sánchez-Tapias JM (eds) Treatment of Liver Diseases. Barcelona: Masson, 1999, pp 61-71.
42. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P et al. A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology 2001; 34: 46-52.
43. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157.
44. Ishikawa SE & Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clinical Endocrinology 2003; 58: 1-17.
45. Kwon TH, Hager H, Nejsum LN et al. Physiology and pathophysiology of renal aquaporins. Seminars in Nephrology 2001; 21: 231-238.
46. Wong F, Blei AT, Blendis LM & Thuluvath PJA. Vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191.
47. Gerbes A, Gulberg V, Gines P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-939.
48. Bichet DG, Groves BM & Schrier RW. Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients. Kidney International 1983; 24: 788-794.
49. Ginès P, Berl T, Bernardi M et al. Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology 1998; 28: 851-864.
50. Angeli P, De Bei E, Dalla Pria M et al. Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology 1992; 15: 651-654.
51. Adrogue HJ & Madias NE. Hyponatremia. New England Journal of Medicine 2000; 342: 1581-1589.
52. Verbalis J. Vasopressin V2 receptor antagonists. Journal of Molecular Endocrinology 2002; 29: 1-9.
53. Cardenas A, Uriz J, Gines P & Arroyo V. Hepatorenal syndrome. Liver Transplantation 2000; 6(4 supplement 1): S63-S71.
54. Caregaro L, Menon F, Angeli P et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Archives of Internal Medicine 1994; 154: 201-205.
55. Sherman DS, Fish DN & Teitelbaum I. Assessing renal function in cirrhotic patients: Problems and pitfalls. American Journal of Kidney Disease 2003; 41: 269-278.
56. Arroyo V, Guevara M & Gines P. Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. Gastroenterology 2002; 122: 1658-1676.
57. Dagher L & Moore K. The hepatorenal syndrome. Gut 2001; 49: 729-737.
58. Arroyo V, Comment Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure [Lancet 1956; 2: 1221-1225]. Journal of Hepatology 2002; 36: 315-320.
59. Menon K & Kamath P. Regional and systemic haemodynamic disturbances in cirrhosis. Clinical Liver Disease 2001; 5: 617-627.
60. Guevara M, Bru C, Ginès P et al. Increased cerebral vascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44.
61. Maroto A, Ginès P, Arroyo V et al. Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology 1993; 17: 788-793.
62. Wiest R & Groszmann R. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002; 35: 478-491.
63. Rockey D & Weisiger R. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-240.
64. Graupera M, Garcia-Pagan JC, Abraldes JG et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37: 172-181.
65. Rockey DC & Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-351.
66. Marteau P, Ballet F, Chazouilleres O et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver. Hepatology 1989; 9: 820-823.
67. Vorobioff J, Bredfeldt JE & Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor maintenance of chronic portal hypertension. American Journal of Physiology 1983; 244: G52-G57.
68. Benoit JN & Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Seminars in Liver Disease 1986; 6: 287-298.
69. Benoit JN & Granger DN. Intestinal microvascular adaptation in chronic portal hypertension in the rat. Gastroenterology 1988; 94: 471-476.
70. Martin PY, Ginès P & Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. New England Journal of Medicine 1998; 339: 533-541.
71. Wiest R & Groszmann R. Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance. Seminars in Liver Disease 1999; 19: 411-426.
72. Moller S, Bendtsen F & Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation 2001; 61: 421-429.
73. Hori N, Wiest R & Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998; 28: 1467-1473.
74. Canill PA, Redmond EM, Hodges R et al. Increased endothelial nitric oxide in the hyperemic vessels of portal hypertensive rats. Journal of Hepatology 1996; 25: 370-378.
75. Martin PY, Ohara M, Ginès P et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. Journal of Clinical Investigation 1998; 101: 235-242.
76. Niederberger M, Martin PY, Ginès P et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-1630.
77. La Villa G, Barletta E, Pantaleo P et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27.
78. Garcia-Tsao G, Lee FY, Barden GE & West A. Bacterial translocation in acute and chronic portal hypertension. Gastroenterology 1995; 108: 1835-1841.
79. Goyal RK & Irano I. The enteric nervous system. New England Journal of Medicine 1996; 334: 1106-1115.
80. Moore K, Wendon J, Frazer M et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. New England Journal of Medicine 1992; 327: 1774-1778.
81. Ginès P, Jiménez W, Arroyo V et al. Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology 1988; 8: 636-642.
82. Warner L, Skorecki K, Blendis LM & Epstein M. Atrial natriuretic factor and liver disease. Hepatology 1993; 17: 500-513.
83. LaVilla G, Laffi G & Gentilini P. Atrial natriuretic peptide and other natriuretic factors in cirrhosis. In Arroyo V, Ginès P, Rodés J & Schrier RW (eds) Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell Science, 1999, pp 231-248.